China becomes Brazil's top buyer of biologicals

China was not on the radar as a major destination for Brazilian biological products just one year ago. In 2024, it ranked 14th, accounting for US$2.7 million and a 2.2% share of total exports in the category. By 2025, it leads the pack — US$13.5 million FOB and 10.5% of the market. The product category is HS 8307 3002, which covers vaccines, antisera, immunological products derived from biotechnology, microbial cultures, and related preparations. It is a broad chapter, but in Brazil's export data the commercial weight tends to sit in veterinary vaccines and biotech-derived therapeutics.

Who moved

Thirteen positions up in a single year is not a gradual drift — it is a structural break. In 2024, China was a peripheral buyer, likely purchasing specific lots without a systematic commercial relationship. In 2025, it is the single largest destination in the category. The scale of the jump points to a regulatory event rather than a price-driven shift. Biological products face high technical barriers: market access in China requires approval through the NMPA (formerly CFDA), which involves local technical reviews, plant inspections, and licensing processes that can span years. When the export volume appears in the trade data, the regulatory work is already done. What the 2025 number reflects is the commercial phase of a process that likely began well before that.

Brazil is a significant global producer of veterinary vaccines. Its biotech sector — anchored by Fiocruz and a cluster of private labs — has established export relationships across Latin America and parts of Africa. The opening of the Chinese market for a Brazilian biological product represents a meaningful market-access gain, one that tends to be sticky once established.

Operational impact

For Brazilian exporters, the immediate implication is scale opportunity. China's veterinary biologicals market is one of the largest in the world. The country holds Asia's biggest cattle herd and is experiencing rapid growth in its animal-protein industry — a structural driver for demand in veterinary vaccines and diagnostics.

On the logistics side, biologicals require cold-chain transport, certified packaging, and stringent sanitary documentation on both ends. For the volume levels now being recorded — US$13.5 million — the exporter is likely managing a combination of air freight for smaller temperature-sensitive lots and refrigerated containers for bulk shipments. Specialized logistics partners with China-specific cold-chain experience become a critical operational variable.

Payment terms and contract structures in the Chinese biologicals market often favor longer-cycle agreements tied to procurement cycles — another reason why the 2025 data likely reflects a contract that was negotiated well in advance.

Scenario if the trend holds

The 2025 data compares January–April 2026 against the same window in 2025. If the pace sustains through the full year, China will consolidate as a structural partner — not an opportunistic buyer — in Brazil's biological exports.

Two indicators to follow: first, whether Southeast Asian markets — Vietnam, Thailand, Indonesia — begin appearing in the ranking with growing volumes, suggesting that Brazil's regional regulatory approvals are compounding. Second, whether the share continues to expand or plateaus around 10%. A plateau would indicate a specific product or contract; continued expansion would suggest a broader commercial relationship is deepening.

For the sector, the China breakthrough is a market-access proof point. Regulatory approvals in Asia do not transfer automatically between jurisdictions, but each approval opens a credible pathway for the next one.

What this means for you

For exporters: China as the #1 buyer of Brazilian biologicals is a market-access credential. Use it to accelerate registration processes in other Asian markets — Vietnam, Indonesia, Thailand — while the commercial relationship is active and volumes are visible.

For importers: biological products exported to China are predominantly B2B inputs — veterinary vaccines and biotech intermediates. If you source these domestically, monitor whether growing export demand begins to affect local availability or pricing.

Source: MDIC ComexStat